|
EP2694640B1
(en)
|
2011-04-08 |
2017-10-18 |
Baylor College Of Medicine |
Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
|
|
EP2814846B1
(en)
|
2012-02-13 |
2020-01-08 |
Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
|
CA3285826A1
(en)
|
2012-02-22 |
2026-03-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
|
|
AU2013246443B2
(en)
|
2012-04-11 |
2017-04-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors targeting B-cell maturation antigen
|
|
US20130280220A1
(en)
*
|
2012-04-20 |
2013-10-24 |
Nabil Ahmed |
Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
|
|
KR20150029714A
(ko)
|
2012-07-13 |
2015-03-18 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강
|
|
LT2884999T
(lt)
|
2012-08-20 |
2021-04-12 |
Fred Hutchinson Cancer Research Center |
Ląstelinės imunoterapijos būdas ir kompozicijos
|
|
EP2934532B1
(en)
|
2012-12-20 |
2019-10-23 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
SG11201505896YA
(en)
|
2013-02-20 |
2015-09-29 |
Novartis Ag |
Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
|
|
US9587237B2
(en)
|
2013-03-14 |
2017-03-07 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
|
US20140274801A1
(en)
*
|
2013-03-14 |
2014-09-18 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified t cells
|
|
US9499855B2
(en)
|
2013-03-14 |
2016-11-22 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
|
EP2970372B1
(en)
|
2013-03-15 |
2020-09-30 |
Celgene Corporation |
Modified t lymphocytes
|
|
US9657105B2
(en)
|
2013-03-15 |
2017-05-23 |
City Of Hope |
CD123-specific chimeric antigen receptor redirected T cells and methods of their use
|
|
DK2992020T3
(da)
*
|
2013-05-03 |
2020-02-10 |
Ohio State Innovation Foundation |
Cs1-specifik kimær antigenreceptor-manipulerede immuneffektorceller
|
|
EP3027755B1
(en)
*
|
2013-08-02 |
2019-10-09 |
The Regents of The University of California |
Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
|
|
AU2014337367B2
(en)
|
2013-10-15 |
2020-04-30 |
The Scripps Research Institute |
Peptidic chimeric antigen receptor T cell switches and uses thereof
|
|
AU2014337385B2
(en)
*
|
2013-10-15 |
2020-04-30 |
The Scripps Research Institute |
Chimeric antigen receptor T cell switches and uses thereof
|
|
US20160250258A1
(en)
*
|
2013-10-31 |
2016-09-01 |
Fred Hutchinson Cancer Research Center |
Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
|
|
EP3858379A1
(en)
*
|
2013-11-21 |
2021-08-04 |
Autolus Limited |
Cell
|
|
US10676528B2
(en)
*
|
2013-12-06 |
2020-06-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
|
|
NZ759969A
(en)
*
|
2013-12-20 |
2022-12-23 |
Fred Hutchinson Cancer Center |
Tagged chimeric effector molecules and receptors thereof
|
|
WO2015092024A2
(en)
*
|
2013-12-20 |
2015-06-25 |
Cellectis |
Method of engineering multi-input signal sensitive t cell for immunotherapy
|
|
CN107074957B
(zh)
*
|
2014-01-13 |
2021-05-07 |
希望之城公司 |
在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
|
|
US10189908B2
(en)
|
2014-02-05 |
2019-01-29 |
The University Of Chicago |
Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants
|
|
ES2959480T3
(es)
*
|
2014-02-07 |
2024-02-26 |
Univ Mcmaster |
Acoplador de células T - antígeno trifuncional y métodos y usos del mismo
|
|
JP6665102B2
(ja)
*
|
2014-02-21 |
2020-03-13 |
セレクティスＣｅｌｌｅｃｔｉｓ |
制御性ｔ細胞をインサイチューで阻害するための方法
|
|
CN122399016A
(zh)
|
2014-03-15 |
2026-07-17 |
诺华股份有限公司 |
使用嵌合抗原受体治疗癌症
|
|
TR201910814T4
(tr)
|
2014-03-19 |
2019-08-21 |
Cellectis |
Kanser immünoterapisi için cd123 spesifik kimerik antijen reseptörleri.
|
|
CN104974261B
(zh)
*
|
2014-04-01 |
2019-06-14 |
三生国健药业（上海）股份有限公司 |
重组抗her2/ps双特异性抗体、其制备方法和应用
|
|
ES2765710T3
(es)
|
2014-04-03 |
2020-06-10 |
Cellectis |
Receptores de antígeno quimérico específicos de CD33 para la inmunoterapia del cáncer
|
|
SG10201808811QA
(en)
*
|
2014-04-10 |
2018-11-29 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Method and compositions for cellular immunotherapy
|
|
US20170158749A1
(en)
*
|
2014-04-23 |
2017-06-08 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (car) and methods for making and using the same
|
|
IL292038B2
(en)
|
2014-04-23 |
2024-12-01 |
Juno Therapeutics Inc |
Methods for enriching or producing immune cell populations for adoptive therapy
|
|
US9975960B2
(en)
|
2014-05-09 |
2018-05-22 |
Samsung Electronics Co., Ltd. |
Anti-HER2 antibody and anti-c-Met/anti-HER2 bispecific antibodies comprising the same
|
|
JP6682509B2
(ja)
*
|
2014-05-14 |
2020-04-15 |
カースゲン セラピューティクス リミテッドＣａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ |
キメラ抗原受容体タンパク質をコードする核酸およびキメラ抗原受容体タンパク質を発現するｔリンパ球
|
|
US11041021B2
(en)
|
2014-05-23 |
2021-06-22 |
University Of Florida Research Foundation, Incorporated |
Car based immunotherapy
|
|
ES2836743T3
(es)
*
|
2014-06-02 |
2021-06-28 |
Us Health |
Receptores de antígeno quiméricos que seleccionan como diana CD-19
|
|
GB201506423D0
(en)
|
2015-04-15 |
2015-05-27 |
Tc Biopharm Ltd |
Gamma delta T cells and uses thereof
|
|
US10738278B2
(en)
|
2014-07-15 |
2020-08-11 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
|
EP3169703B2
(en)
|
2014-07-16 |
2023-12-13 |
Hinrich Abken |
Chimeric antigen receptor and its use
|
|
JP6831777B2
(ja)
|
2014-07-21 |
2021-02-17 |
ノバルティス アーゲー |
Ｃｄ３３キメラ抗原受容体を使用する癌の処置
|
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
|
|
BR112017000939A2
(pt)
|
2014-07-21 |
2017-11-14 |
Novartis Ag |
tratamento de câncer usando um receptor antigênico quimérico de cll-1
|
|
AU2015292744C1
(en)
|
2014-07-21 |
2021-01-21 |
Novartis Ag |
Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
|
|
US10752684B2
(en)
|
2014-07-29 |
2020-08-25 |
Cellectis |
ROR1 (NTRKR1) specific chimeric antigen receptors for cancer immunotherapy
|
|
WO2016016343A1
(en)
*
|
2014-07-31 |
2016-02-04 |
Cellectis |
Ror1 specific multi-chain chimeric antigen receptor
|
|
CA2957929A1
(en)
*
|
2014-08-12 |
2016-02-18 |
Anthrogenesis Corporation |
Car-t lymphocytes engineered to home to lymph node b cell zone, skin, or gastrointestinal tract
|
|
TWI751102B
(zh)
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
對ｃｄ１９具專一性之抗體及嵌合抗原受體
|
|
DK3186284T3
(da)
*
|
2014-08-28 |
2022-05-09 |
Bioatla Inc |
Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
|
|
US11111288B2
(en)
*
|
2014-08-28 |
2021-09-07 |
Bioatla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
US10513699B2
(en)
*
|
2014-09-03 |
2019-12-24 |
Bioatla, Llc |
Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
|
|
WO2016034666A1
(en)
*
|
2014-09-04 |
2016-03-10 |
Cellectis |
Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
|
|
US10577417B2
(en)
|
2014-09-17 |
2020-03-03 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
ES2738705T3
(es)
*
|
2014-09-19 |
2020-01-24 |
Hope City |
Linfocitos T de receptor de antígeno quimérico coestimulante que se dirigen a IL13R 2
|
|
RS63601B1
(sr)
*
|
2014-10-09 |
2022-10-31 |
Univ Yamaguchi |
Vektor ekspresije car i t ćelije koje eksprimiraju car
|
|
MA41538A
(fr)
*
|
2014-10-17 |
2017-12-26 |
Baylor College Medicine |
Cellules immunitaires bipartites et tripartites de signalisation
|
|
BR112017008042A2
(pt)
|
2014-10-20 |
2017-12-26 |
Juno Therapeutics Inc |
métodos e composições para dosagem em terapia de célula adotiva
|
|
EP3217989B1
(en)
|
2014-10-31 |
2022-01-05 |
The Trustees of the University of Pennsylvania |
Compositions and methods of stimulating and expanding t cells
|
|
PL3212225T3
(pl)
*
|
2014-10-31 |
2026-03-30 |
The Trustees Of The University Of Pennsylvania |
Sposoby i kompozycje zmodyfikowanych limfocytów t
|
|
JP6740234B2
(ja)
|
2014-11-05 |
2020-08-12 |
ジュノー セラピューティクス インコーポレイテッド |
形質導入および細胞プロセシングのための方法
|
|
AR102417A1
(es)
*
|
2014-11-05 |
2017-03-01 |
Lilly Co Eli |
Anticuerpos biespecíficos anti-tnf- / anti-il-23
|
|
EP3227323B1
(en)
|
2014-12-03 |
2020-08-05 |
Juno Therapeutics, Inc. |
Methods and compositions for adoptive cell therapy
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
CN107429253B
(zh)
*
|
2014-12-05 |
2021-11-05 |
希望之城公司 |
Cs1靶向性嵌合抗原受体修饰的t细胞
|
|
WO2016100232A1
(en)
*
|
2014-12-15 |
2016-06-23 |
The Regents Of The University Of California |
Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
|
|
EP3234120B1
(en)
|
2014-12-15 |
2025-09-03 |
The Regents of the University of California |
Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
|
|
RU2017125531A
(ru)
|
2014-12-19 |
2019-01-21 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Химерные антигенные рецепторы и способы их применения
|
|
HRP20240357T1
(hr)
*
|
2014-12-24 |
2024-06-07 |
Autolus Limited |
Stanica
|
|
HK1246180A1
(zh)
*
|
2014-12-31 |
2018-09-07 |
Celgene Corporation |
使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法
|
|
MA41346A
(fr)
|
2015-01-12 |
2017-11-21 |
Juno Therapeutics Inc |
Eléments régulateurs post-transcriptionnels d'hépatite modifiée
|
|
US20160208018A1
(en)
|
2015-01-16 |
2016-07-21 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for ror1
|
|
EP3250602A1
(en)
|
2015-01-26 |
2017-12-06 |
Cellectis |
T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
|
|
EP3250611B1
(en)
|
2015-01-26 |
2021-04-21 |
The University of Chicago |
Car t-cells recognizing cancer-specific il 13r-alpha2
|
|
EP3250609A4
(en)
|
2015-01-26 |
2018-07-11 |
The University of Chicago |
Il13ra alpha 2 binding agents and use thereof in cancer treatment
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
CN105985444B
(zh)
*
|
2015-02-05 |
2024-02-13 |
博生吉安科细胞技术有限公司 |
一种嵌合抗原受体、以及快速构建嵌合抗原受体的方法及应用
|
|
US10647778B2
(en)
|
2015-02-09 |
2020-05-12 |
University Of Florida Research Foundation, Incorporated |
Bi-specific chimeric antigen receptor and uses thereof
|
|
US11248058B2
(en)
|
2015-02-19 |
2022-02-15 |
University Of Florida Research Foundation, Inc. |
Chimeric antigen receptors and uses thereof
|
|
CN107530424A
(zh)
|
2015-02-20 |
2018-01-02 |
俄亥俄州国家创新基金会 |
针对nkg2d和肿瘤相关抗原的二价抗体
|
|
US10808230B2
(en)
*
|
2015-02-24 |
2020-10-20 |
Board Of Regents, The University Of Texas System |
Selection methods for genetically-modified T cells
|
|
CA2977106A1
(en)
*
|
2015-02-27 |
2016-09-01 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
|
|
BR112017018770A2
(pt)
|
2015-03-02 |
2018-04-17 |
Innovative Cellular Therapeutics CO., LTD. |
redução da tolerância imunológica induzida por pd-l1
|
|
SG11201707182WA
(en)
*
|
2015-03-05 |
2017-10-30 |
Hutchinson Fred Cancer Res |
Immunomodulatory fusion proteins and uses thereof
|
|
WO2016149578A1
(en)
*
|
2015-03-19 |
2016-09-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Dual specific anti-cd22-anti-cd19 chimeric antigen receptors
|
|
US10800828B2
(en)
|
2015-03-26 |
2020-10-13 |
The Scripps Research Institute |
Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
|
|
EA039192B1
(ru)
*
|
2015-03-30 |
2021-12-16 |
Селджин Корпорейшн |
Способ лечения рака и набор для лечения рака
|
|
CN108367057B
(zh)
|
2015-04-06 |
2022-11-22 |
赛通免疫股份有限公司 |
用于胶质母细胞瘤的egfr导向的car疗法
|
|
PL3280729T3
(pl)
|
2015-04-08 |
2022-08-22 |
Novartis Ag |
Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
|
|
US11091546B2
(en)
|
2015-04-15 |
2021-08-17 |
The Scripps Research Institute |
Optimized PNE-based chimeric receptor T cell switches and uses thereof
|
|
WO2016166568A1
(en)
|
2015-04-16 |
2016-10-20 |
Juno Therapeutics Gmbh |
Methods, kits and apparatus for expanding a population of cells
|
|
MA41962A
(fr)
*
|
2015-04-23 |
2018-02-28 |
Baylor College Medicine |
Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t
|
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
GB201507111D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
|
EP3288570A4
(en)
|
2015-04-29 |
2018-11-21 |
Fred Hutchinson Cancer Research Center |
Modified stem cells and uses thereof
|
|
GB201507368D0
(en)
*
|
2015-04-30 |
2015-06-17 |
Ucl Business Plc |
Cell
|
|
CN107849102B
(zh)
*
|
2015-05-15 |
2022-05-13 |
希望之城 |
嵌合抗原受体组合物
|
|
EP3770168A1
(en)
|
2015-05-18 |
2021-01-27 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
CN108137669B
(zh)
*
|
2015-05-18 |
2023-02-17 |
优瑞科生物技术公司 |
抗ror1嵌合抗原受体
|
|
TW201706300A
(zh)
*
|
2015-05-20 |
2017-02-16 |
瑟勒提斯公司 |
用於癌症免疫療法之抗－ｇｄ３專一性嵌合抗原受體
|
|
WO2016191587A1
(en)
|
2015-05-28 |
2016-12-01 |
Armo Biosciences, Inc. |
Pegylated interleukin-10 for use in treating cancer
|
|
MX2017015239A
(es)
|
2015-05-29 |
2018-02-19 |
Juno Therapeutics Inc |
Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas.
|
|
TWI833684B
(zh)
|
2015-06-25 |
2024-03-01 |
美商生物細胞基因治療有限公司 |
嵌合抗原受體（ｃａｒ）、組合物及其使用方法
|
|
US11173179B2
(en)
|
2015-06-25 |
2021-11-16 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
|
|
CN107709356A
(zh)
*
|
2015-06-26 |
2018-02-16 |
南加利福尼亚大学 |
用于肿瘤特异性活化的掩蔽嵌合抗原受体t细胞
|
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
|
WO2017023859A1
(en)
|
2015-07-31 |
2017-02-09 |
Memorial Sloan-Kettering Cancer Center |
Antigen-binding proteins targeting cd56 and uses thereof
|
|
US11667691B2
(en)
|
2015-08-07 |
2023-06-06 |
Novartis Ag |
Treatment of cancer using chimeric CD3 receptor proteins
|
|
MX2018001568A
(es)
*
|
2015-08-07 |
2019-04-25 |
Seattle Children´S Hospital Dba Seattle Children´S Res Institute |
Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos.
|
|
KR20240149974A
(ko)
*
|
2015-08-11 |
2024-10-15 |
고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 |
항체
|
|
CN105384825B
(zh)
*
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
GB201514874D0
(en)
|
2015-08-20 |
2015-10-07 |
Autolus Ltd |
Cell
|
|
GB201514875D0
(en)
|
2015-08-20 |
2015-10-07 |
Autolus Ltd |
Receptor
|
|
SG10201913151TA
(en)
|
2015-09-09 |
2020-03-30 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Genetic engineering of macrophages for immunotherapy
|
|
EP3747472B1
(en)
|
2015-09-15 |
2024-04-03 |
Acerta Pharma B.V. |
Therapeutic combinations of a cd19 inhibitor and a btk inhibitor
|
|
JP6991131B2
(ja)
*
|
2015-09-22 |
2022-02-03 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
Ｈｉｖ感染症を処置するためにｔ細胞を再度方向付ける方法
|
|
ES2768957T3
(es)
|
2015-09-24 |
2020-06-24 |
Abvitro Llc |
Composiciones de anticuerpos contra el VIH y métodos de uso
|
|
AU2016326734B2
(en)
|
2015-09-25 |
2022-07-07 |
Abvitro Llc |
High throughput process for T cell receptor target identification of natively-paired T cell receptor sequences
|
|
US11365391B2
(en)
|
2015-09-28 |
2022-06-21 |
Trustees Of Dartmouth College |
Chimeric antigen receptor anti-inflammatory cells and methods of use
|
|
MY206406A
(en)
|
2015-10-02 |
2024-12-16 |
Hoffmann La Roche |
Bispecific antibodies specific for a costimulatory tnf receptor
|
|
WO2017059900A1
(en)
*
|
2015-10-07 |
2017-04-13 |
Biontech Cell & Gene Therapies Gmbh |
Antigen receptors and uses thereof
|
|
KR102908806B1
(ko)
|
2015-10-22 |
2026-01-07 |
주노 테라퓨틱스 게엠베하 |
세포의 배양 방법 및 이를 위한 키트와 장치
|
|
MA45489A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés de culture de cellules, kits et appareil associés
|
|
RU2761555C2
(ru)
|
2015-10-22 |
2021-12-09 |
Джуно Терапьютикс Гмбх |
Способы, наборы, средства и устройства для трансдукции
|
|
EP3368571B1
(en)
*
|
2015-10-30 |
2022-12-07 |
The Regents of The University of California |
Transforming growth factor-beta-responsive polypeptides and their methods for use
|
|
US11020429B2
(en)
|
2015-11-05 |
2021-06-01 |
Juno Therapeutics, Inc. |
Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
|
|
MX2018005618A
(es)
|
2015-11-05 |
2018-08-01 |
Juno Therapeutics Inc |
Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados.
|
|
HUE054131T2
(hu)
|
2015-11-19 |
2021-08-30 |
Revitope Ltd |
Funkcionális ellenanyag-fragmens-komplementáció nemkívánatos sejtek elpusztítására szolgáló kétkomponensû rendszerben
|
|
ES2987957T3
(es)
|
2015-11-23 |
2024-11-18 |
Novartis Ag |
Vectores de transferencia lentivirales optimizados y usos de los mismos
|
|
MX2018006789A
(es)
|
2015-12-03 |
2019-02-13 |
Juno Therapeutics Inc |
Receptores quimericos modificados y composiciones y metodos relacionados.
|
|
US20200297760A1
(en)
|
2015-12-03 |
2020-09-24 |
Juno Therapeutics, Inc. |
Compositions and methods for reducing immune responses against chimeric antigen receptors
|
|
WO2017096331A1
(en)
|
2015-12-04 |
2017-06-08 |
Juno Therapeutics, Inc. |
Methods and compositions related to toxicity associated with cell therapy
|
|
KR20180099768A
(ko)
|
2015-12-30 |
2018-09-05 |
노파르티스 아게 |
증진된 효능을 갖는 면역 이펙터 세포 요법
|
|
EP3419618A4
(en)
*
|
2016-02-26 |
2019-11-06 |
iCell Gene Therapeutics, LLC |
CHIMERIC ANTIGEN RECEPTORS (CAR) AGAINST HEMATOLOGIC MALIGNOMES, COMPOSITIONS AND METHODS OF USE THEREOF
|
|
SG11201807489PA
(en)
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
MA43759A
(fr)
|
2016-03-16 |
2018-11-28 |
Jason Connor |
Procédés de conception adaptative d'un régime de traitement et traitements associés
|
|
WO2017161208A1
(en)
|
2016-03-16 |
2017-09-21 |
Juno Therapeutics, Inc. |
Methods for determining dosing of a therapeutic agent and related treatments
|
|
MX2018010974A
(es)
|
2016-03-17 |
2019-03-28 |
Univ Yamaguchi |
Célula inmunocompetente y vector de expresión que expresa factores reguladores de la función inmune.
|
|
US11325948B2
(en)
|
2016-03-19 |
2022-05-10 |
Exuma Biotech Corp. |
Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
|
|
CN108884460B
(zh)
*
|
2016-03-19 |
2023-04-28 |
埃克苏马生物技术公司 |
淋巴细胞转导及其扩增调节的方法与组合物
|
|
US12590321B2
(en)
|
2016-03-19 |
2026-03-31 |
Exuma Biotech Corp. |
Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof
|
|
US11111505B2
(en)
|
2016-03-19 |
2021-09-07 |
Exuma Biotech, Corp. |
Methods and compositions for transducing lymphocytes and regulating the activity thereof
|
|
CN109476743A
(zh)
|
2016-03-22 |
2019-03-15 |
西雅图儿童医院(以西雅图儿童研究所名义营业) |
预防或缓解毒性的早期干预方法
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
CA3019835A1
(en)
|
2016-04-08 |
2017-10-12 |
Purdue Research Foundation |
Methods and compositions for car t cell therapy
|
|
WO2017177217A2
(en)
*
|
2016-04-08 |
2017-10-12 |
Unum Therapeutics |
Chimeric receptors and uses thereof in immune therapy
|
|
CA3020599A1
(en)
*
|
2016-04-15 |
2017-10-19 |
The Children's Hospital Of Philadelphia |
Compositions and methods of chimeric alloantigen receptor t cells
|
|
US20230071283A1
(en)
|
2016-04-15 |
2023-03-09 |
Aimee S. Payne |
Compositions and methods for selective protein expression
|
|
JP7198670B2
(ja)
*
|
2016-04-20 |
2023-01-04 |
フレッド ハッチンソン キャンサー センター |
免疫調整性ｉｌ２ｒ融合タンパク質およびその使用
|
|
WO2017186853A1
(en)
*
|
2016-04-27 |
2017-11-02 |
Bcrt Holding Bv |
T cell-based bi-specific immunotherapeutics
|
|
WO2017190096A1
(en)
|
2016-04-29 |
2017-11-02 |
University Of Florida Research Foundation Incorporated |
Chimeric antigen receptors and uses thereof
|
|
WO2017192536A1
(en)
|
2016-05-02 |
2017-11-09 |
University Of Kansas |
Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
|
|
EP3452499A2
(en)
|
2016-05-06 |
2019-03-13 |
Juno Therapeutics, Inc. |
Genetically engineered cells and methods of making the same
|
|
EP4122958A1
(en)
|
2016-05-13 |
2023-01-25 |
BioAtla, Inc. |
Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
|
CA3025523A1
(en)
|
2016-05-27 |
2017-11-30 |
Aadigen, Llc |
Peptides and nanoparticles for intracellular delivery of genome-editing molecules
|
|
WO2017210689A1
(en)
|
2016-06-03 |
2017-12-07 |
Memorial Sloan-Kettering Cancer Center |
Adoptive cell therapies as early treatment options
|
|
WO2017214207A2
(en)
|
2016-06-06 |
2017-12-14 |
Juno Therapeutics, Inc. |
Methods for the treatment of b cell malignancies using adoptive cell therapy
|
|
CN118652336A
(zh)
|
2016-06-08 |
2024-09-17 |
普瑞赛格恩公司 |
Cd33特异性嵌合抗原受体
|
|
CN109562126A
(zh)
|
2016-06-24 |
2019-04-02 |
美商生物细胞基因治疗有限公司 |
嵌合抗原受体(car)、组合物及其使用方法
|
|
US20200182884A1
(en)
|
2016-06-27 |
2020-06-11 |
Juno Therapeutics, Inc. |
Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
|
|
JP7054397B2
(ja)
|
2016-06-27 |
2022-04-13 |
ジュノー セラピューティクス インコーポレイテッド |
Ｍｈｃ－ｅ拘束性エピトープ、結合分子ならびに関連する方法および使用
|
|
CA3030003A1
(en)
*
|
2016-07-08 |
2018-01-11 |
F1 Oncology, Inc. |
Methods and compositions for transducing lymphocytes and regulating the activity thereof
|
|
JP7295795B2
(ja)
|
2016-07-29 |
2023-06-21 |
ジュノー セラピューティクス インコーポレイテッド |
免疫調節ポリペプチドならびに関連する組成物および方法
|
|
JP7483373B2
(ja)
|
2016-07-29 |
2024-05-15 |
ジュノー セラピューティクス インコーポレイテッド |
複製可能ウイルスの存在または非存在を評価するための方法
|
|
MA45784A
(fr)
|
2016-07-29 |
2019-06-05 |
Juno Therapeutics Inc |
Anticorps anti-idiotypes dirigés contre anti-cd19 anticorps
|
|
SG11201900885VA
(en)
|
2016-08-01 |
2019-02-27 |
Novartis Ag |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
|
WO2018026953A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
US12350349B2
(en)
|
2016-08-03 |
2025-07-08 |
Washington University |
Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors
|
|
PL3896091T3
(pl)
*
|
2016-08-10 |
2024-04-29 |
Legend Biotech Ireland Limited |
Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania
|
|
CN118546961A
(zh)
|
2016-08-26 |
2024-08-27 |
贝勒医学院 |
用于细胞治疗的组成型活性细胞因子受体
|
|
CN117298260A
(zh)
*
|
2016-09-02 |
2023-12-29 |
莱蒂恩技术公司 |
用DuoCAR治疗癌症的组合物和方法
|
|
CA3039136A1
(en)
|
2016-09-02 |
2018-03-08 |
The Regents Of The University Of California |
Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
|
|
MX2019002765A
(es)
|
2016-09-12 |
2019-05-09 |
Juno Therapeutics Inc |
Montajes de bolsa de biorreactor de perfusion.
|
|
CN107841506B
(zh)
*
|
2016-09-20 |
2021-03-16 |
上海恒润达生生物科技有限公司 |
靶向间皮素的嵌合抗原受体及其用途
|
|
WO2018057585A1
(en)
*
|
2016-09-21 |
2018-03-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use
|
|
EP3515493A4
(en)
*
|
2016-09-23 |
2020-08-19 |
University of Southern California |
CHEMERICAL ANTIGEN RECEPTORS, COORESPONDENT COMPOSITIONS AND METHODS OF USE
|
|
CN110087657A
(zh)
|
2016-09-28 |
2019-08-02 |
阿托莎遗传股份有限公司 |
过继细胞治疗的方法
|
|
WO2018064602A1
(en)
*
|
2016-09-30 |
2018-04-05 |
Baylor College Of Medicine |
Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease
|
|
CN110199015A
(zh)
*
|
2016-09-30 |
2019-09-03 |
波赛达治疗公司 |
修饰干细胞记忆t细胞、其制造方法与使用方法
|
|
US20190119636A1
(en)
|
2017-10-23 |
2019-04-25 |
Poseida Therapeutics, Inc. |
Modified stem cell memory t cells, methods of making and methods of using same
|
|
KR20190062505A
(ko)
|
2016-10-03 |
2019-06-05 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Hpv-특이적 결합 분자
|
|
JP7467117B2
(ja)
*
|
2016-10-07 |
2024-04-15 |
ノバルティス アーゲー |
癌の治療のためのキメラ抗原受容体
|
|
BR112019007100A2
(pt)
|
2016-10-07 |
2019-06-25 |
Tcr2 Therapeutics Inc |
composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
|
|
CA3039797A1
(en)
*
|
2016-10-11 |
2018-04-19 |
Minerva Biotechnologies Corporation |
Humanized anti-muc1* antibodies and use of cleavage enzyme
|
|
EP3525803B1
(en)
|
2016-10-13 |
2022-12-07 |
Juno Therapeutics, Inc. |
Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
|
|
EP3526257A2
(en)
*
|
2016-10-14 |
2019-08-21 |
Dana-Farber Cancer Institute, Inc. |
Modular tetravalent bispecific antibody platform
|
|
EP3529268B1
(en)
|
2016-10-19 |
2025-02-26 |
The Scripps Research Institute |
Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
|
|
CA3042049A1
(en)
|
2016-11-03 |
2018-05-11 |
Juno Therapeutics, Inc. |
Combination therapy of a t cell therapy and a btk inhibitor
|
|
MA46716A
(fr)
|
2016-11-03 |
2019-09-11 |
Juno Therapeutics Inc |
Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie
|
|
CN110177803A
(zh)
|
2016-11-22 |
2019-08-27 |
T细胞受体治疗公司 |
用于使用融合蛋白进行tcr重新编程的组合物和方法
|
|
JP2019536460A
(ja)
|
2016-12-03 |
2019-12-19 |
ジュノー セラピューティクス インコーポレイテッド |
Ｃａｒ−ｔ細胞の調節方法
|
|
US11590167B2
(en)
|
2016-12-03 |
2023-02-28 |
Juno Therapeutic, Inc. |
Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
|
|
US20200078400A1
(en)
|
2016-12-03 |
2020-03-12 |
Juno Therapeutics, Inc. |
Methods for determining car-t cells dosing
|
|
WO2018106732A1
(en)
|
2016-12-05 |
2018-06-14 |
Juno Therapeutics, Inc. |
Production of engineered cells for adoptive cell therapy
|
|
WO2018111763A1
(en)
|
2016-12-12 |
2018-06-21 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
|
|
CA3045667A1
(en)
*
|
2016-12-13 |
2018-06-21 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
|
|
WO2018111340A1
(en)
|
2016-12-16 |
2018-06-21 |
Novartis Ag |
Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
|
|
WO2018118494A2
(en)
*
|
2016-12-22 |
2018-06-28 |
Xiaotong Song |
Use of car-modified human natural killer cells to treat cancer
|
|
BR112019012950A2
(pt)
|
2016-12-23 |
2019-11-26 |
Macrogenics, Inc. |
molécula de ligação a adam9, composição farmacêutica, uso da molécula de ligação a adam9 e método para tratar uma doença ou condição associada ou caracterizada pela expressão de adam9 em um indivíduo
|
|
CN108250301A
(zh)
*
|
2016-12-29 |
2018-07-06 |
天津天锐生物科技有限公司 |
一种多靶点嵌合抗原受体
|
|
CN108264566B
(zh)
*
|
2016-12-30 |
2021-05-14 |
惠和生物技术(上海)有限公司 |
一种融合抗cd3抗体结构域和t细胞正共刺激分子配体的双特异性分子及其应用
|
|
WO2018132518A1
(en)
|
2017-01-10 |
2018-07-19 |
Juno Therapeutics, Inc. |
Epigenetic analysis of cell therapy and related methods
|
|
US11578115B2
(en)
|
2017-01-10 |
2023-02-14 |
The General Hospital Corporation |
Chimeric antigen receptors based on alternative signal 1 domains
|
|
EP3568406A4
(en)
|
2017-01-10 |
2020-10-21 |
The General Hospital Corporation |
T LYMPHOCYTES EXPRESSING A CHEMERICAL ANTIGENIC RECEPTOR
|
|
EP3571221A2
(en)
|
2017-01-20 |
2019-11-27 |
Juno Therapeutics GmbH |
Cell surface conjugates and related cell compositions and methods
|
|
US11535662B2
(en)
|
2017-01-26 |
2022-12-27 |
Novartis Ag |
CD28 compositions and methods for chimeric antigen receptor therapy
|
|
US20190375815A1
(en)
|
2017-01-31 |
2019-12-12 |
Novartis Ag |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
|
AU2018219226B2
(en)
|
2017-02-07 |
2024-12-19 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
|
|
CN108395482B
(zh)
|
2017-02-08 |
2021-02-05 |
西比曼生物科技（香港）有限公司 |
一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
|
|
IL268349B2
(en)
|
2017-02-17 |
2024-08-01 |
Hutchinson Fred Cancer Res |
Combination therapies for treatment of bcma-related cancers and autoimmune disorders
|
|
MX2019010171A
(es)
|
2017-02-27 |
2019-10-15 |
Juno Therapeutics Inc |
Composiciones, articulos de fabricacion y metodos relacionados con la dosificacion en la terapia celular.
|
|
CN110582288B
(zh)
|
2017-02-28 |
2024-09-20 |
恩多塞特公司 |
用于car t细胞疗法的组合物和方法
|
|
WO2018160731A1
(en)
|
2017-02-28 |
2018-09-07 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
CN110913690A
(zh)
|
2017-03-14 |
2020-03-24 |
朱诺治疗学股份有限公司 |
用于低温储存的方法
|
|
EP3595721B1
(en)
|
2017-03-16 |
2025-07-09 |
The General Hospital Corporation |
Chimeric antigen receptors targeting cd37
|
|
US11725210B2
(en)
|
2017-03-17 |
2023-08-15 |
Fred Hutchinson Cancer Center |
Immunomodulatory fusion proteins and uses thereof
|
|
WO2018178055A1
(en)
*
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
|
WO2018178076A1
(en)
*
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
|
CN110869046B
(zh)
|
2017-03-31 |
2025-02-25 |
塞勒克提斯公司 |
通用型抗cd22嵌合抗原受体工程化的免疫细胞
|
|
CN110402255B
(zh)
*
|
2017-04-04 |
2022-12-02 |
豪夫迈·罗氏有限公司 |
新颖的能够特异性结合cd40和fap的双特异性抗原结合分子
|
|
MX2019012017A
(es)
|
2017-04-07 |
2020-02-12 |
Juno Therapeutics Inc |
Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
|
|
CN110709700A
(zh)
|
2017-04-14 |
2020-01-17 |
朱诺治疗学股份有限公司 |
评估细胞表面糖基化的方法
|
|
CN110891967B
(zh)
|
2017-04-18 |
2025-03-14 |
富士胶片细胞动力公司 |
抗原特异性免疫效应细胞
|
|
JP2020517259A
(ja)
|
2017-04-19 |
2020-06-18 |
ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム |
操作された抗原受容体を発現する免疫細胞
|
|
CN108728458B
(zh)
*
|
2017-04-21 |
2021-11-16 |
上海恒润达生生物科技股份有限公司 |
靶向mesothelin的嵌合抗原受体并联合表达IL-15的方法和用途
|
|
KR20190140943A
(ko)
|
2017-04-24 |
2019-12-20 |
메모리얼 슬로안 케터링 캔서 센터 |
항-cd33 항체 제제
|
|
AU2018260380B2
(en)
|
2017-04-27 |
2025-02-13 |
Juno Therapeutics Gmbh |
Oligomeric particle reagents and methods of use thereof
|
|
PL3618842T3
(pl)
|
2017-05-01 |
2024-02-19 |
Juno Therapeutics, Inc. |
Kombinacja terapii komórkowej i związku immunomodulującego
|
|
AU2018269194B2
(en)
|
2017-05-15 |
2025-05-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bicistronic chimeric antigen receptors and their uses
|
|
IL327498A
(en)
|
2017-06-02 |
2026-05-01 |
Juno Therapeutics Inc |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
|
EP3631468A1
(en)
|
2017-06-02 |
2020-04-08 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods related to toxicity associated with cell therapy
|
|
EP3635132A4
(en)
*
|
2017-06-07 |
2021-05-26 |
Intrexon Corporation |
EXPRESSION OF NOVEL CELL MARKERS
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
CN110997902B
(zh)
|
2017-06-20 |
2021-11-30 |
居里研究所 |
Suv39h1缺陷的免疫细胞
|
|
CN118853581A
(zh)
|
2017-06-21 |
2024-10-29 |
美商生物细胞基因治疗有限公司 |
嵌合抗原受体(CARs)、组合物及其使用方法
|
|
AU2018288863A1
(en)
|
2017-06-22 |
2020-01-30 |
Board Of Regents, The University Of Texas System |
Methods for producing regulatory immune cells and uses thereof
|
|
CN110769898A
(zh)
*
|
2017-06-22 |
2020-02-07 |
南加利福尼亚大学 |
使用嵌合抗原受体工程化自然杀伤细胞作为化学治疗药物运载体的联合癌症疗法
|
|
CN111050545A
(zh)
|
2017-06-29 |
2020-04-21 |
朱诺治疗学股份有限公司 |
评估与免疫疗法相关的毒性的小鼠模型
|
|
JP7280238B2
(ja)
*
|
2017-07-17 |
2023-05-23 |
ヤンセン バイオテツク，インコーポレーテツド |
フィブロネクチンｉｉｉ型ドメインに対する抗原結合領域及びその使用方法
|
|
WO2019014891A1
(zh)
*
|
2017-07-20 |
2019-01-24 |
深圳普瑞金生物药业有限公司 |
一种用于治疗肿瘤的egfr单域抗体cart及其应用
|
|
US11725060B2
(en)
|
2017-07-20 |
2023-08-15 |
Aptevo Reserch and Development LLC |
Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods
|
|
EP4549554A3
(en)
|
2017-07-29 |
2025-08-06 |
Juno Therapeutics, Inc. |
Reagents for expanding cells expressing recombinant receptors
|
|
AU2018309735B2
(en)
*
|
2017-07-31 |
2025-03-13 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy
|
|
EP4516896A3
(en)
|
2017-08-09 |
2025-05-14 |
Juno Therapeutics, Inc. |
Methods and compositions for preparing genetically engineered cells
|
|
KR102755437B1
(ko)
|
2017-08-09 |
2025-01-20 |
주노 쎄러퓨티크스 인코퍼레이티드 |
유전자 조작된 세포 조성물 및 관련 조성물의 제조 방법
|
|
CN109423495A
(zh)
*
|
2017-08-24 |
2019-03-05 |
上海恒润达生生物科技有限公司 |
一种双靶向嵌合抗原受体及其用途
|
|
WO2019046832A1
(en)
|
2017-09-01 |
2019-03-07 |
Juno Therapeutics, Inc. |
GENE EXPRESSION AND EVALUATION OF RISK OF DEVELOPMENT OF TOXICITY FOLLOWING CELL THERAPY
|
|
MA50079A
(fr)
|
2017-09-07 |
2020-07-15 |
Juno Therapeutics Inc |
Procédés d'identification de caractéristiques cellulaires relatives à des réponses associées à une thérapie cellulaire
|
|
CN109517820B
(zh)
|
2017-09-20 |
2021-09-24 |
北京宇繁生物科技有限公司 |
一种靶向HPK1的gRNA以及HPK1基因编辑方法
|
|
US20200268795A1
(en)
*
|
2017-09-22 |
2020-08-27 |
The Regents Of The University Of California |
Interferon-gamma attenuates anti-tumor immune response to checkpoint blockade
|
|
US11952408B2
(en)
|
2017-10-03 |
2024-04-09 |
Juno Therapeutics, Inc. |
HPV-specific binding molecules
|
|
EP3692057B9
(en)
*
|
2017-10-03 |
2023-10-04 |
Precision BioSciences, Inc. |
Modified epidermal growth factor receptor peptides for use in genetically-modified cells
|
|
CA3075886A1
(en)
|
2017-10-10 |
2019-04-18 |
Yamaguchi University |
Enhancer for t-cells or b-cells having memory function, malignant tumor recurrence inhibitor, and inducer for inducing memory function in t-cells or b-cells
|
|
WO2019075385A1
(en)
|
2017-10-12 |
2019-04-18 |
Board Of Regents, The University Of Texas System |
T-LYMPHOCYTE COMPOSITIONS FOR IMMUNOTHERAPY
|
|
EP3694997A4
(en)
|
2017-10-12 |
2021-06-30 |
Mcmaster University |
T cell-antigen coupler with y182t mutation and methods and uses thereof
|
|
SG11202003415XA
(en)
|
2017-10-18 |
2020-05-28 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
US10329543B2
(en)
|
2017-10-23 |
2019-06-25 |
Poseida Therapeutics, Inc. |
Modified stem cell memory T cells, methods of making and methods of using same
|
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
|
WO2019084288A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
METHODS FOR DESIGNING CHIMERIC ANTIGENIC RECEPTOR EXPRESSION CELLS
|
|
BR112020008727A2
(pt)
|
2017-10-30 |
2020-10-20 |
Neuropore Therapies, Inc. |
fenil sulfonil fenil triazol tionas substituídas e usos destas
|
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
|
US11066475B2
(en)
|
2017-11-01 |
2021-07-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
|
|
MA49911A
(fr)
|
2017-11-01 |
2020-06-24 |
Juno Therapeutics Inc |
Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
|
|
CA3081456A1
(en)
|
2017-11-01 |
2019-05-09 |
Editas Medicine, Inc. |
Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
|
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
|
CA3080509A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Process for producing a t cell composition
|
|
US11851679B2
(en)
|
2017-11-01 |
2023-12-26 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
|
WO2019089848A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
|
JP7357626B2
(ja)
|
2017-11-01 |
2023-10-06 |
ジュノー セラピューティクス インコーポレイテッド |
操作された細胞の治療用組成物を生成するためのプロセス
|
|
JP2021502077A
(ja)
|
2017-11-06 |
2021-01-28 |
エディタス・メディシン，インコーポレイテッド |
免疫療法のためのｔ細胞におけるｃｂｌｂのｃｒｉｓｐｒ−ｃａｓ９編集のための方法、組成物および構成要素
|
|
AU2018359907A1
(en)
|
2017-11-06 |
2020-05-07 |
Fred Hutchinson Cancer Center |
Combination of a cell therapy and a gamma secretase inhibitor
|
|
US11802163B2
(en)
|
2017-11-10 |
2023-10-31 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors targeting glypican-3 or mesothelin
|
|
US20200330983A1
(en)
|
2017-11-10 |
2020-10-22 |
Juno Therapeutics, Inc. |
Closed-system cryogenic vessels
|
|
CN108034669B
(zh)
*
|
2017-11-17 |
2021-07-30 |
山东兴瑞生物科技有限公司 |
一种抗vegf基因、及利用其修饰的t细胞、制备方法和应用
|
|
JP2021503885A
(ja)
|
2017-11-22 |
2021-02-15 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
末梢血からの末梢血リンパ球（ｐｂｌ）の拡大培養
|
|
GB201719557D0
(en)
*
|
2017-11-24 |
2018-01-10 |
Autolus Ltd |
Polypeptide
|
|
MA51210A
(fr)
|
2017-12-01 |
2020-10-07 |
Juno Therapeutics Inc |
Procédés de dosage et de modulation de cellules génétiquement modifiées
|
|
CN119193493A
(zh)
|
2017-12-08 |
2024-12-27 |
朱诺治疗学股份有限公司 |
生产工程化t细胞组合物的过程
|
|
AU2018379091A1
(en)
|
2017-12-08 |
2020-06-25 |
Juno Therapeutics, Inc. |
Serum-free media formulation for culturing cells and methods of use thereof
|
|
BR112020011223A2
(pt)
|
2017-12-08 |
2020-11-17 |
Juno Therapeutics Inc |
marcadores fenotípicos para terapia celular e mé-todos relacionados
|
|
EP3724225A1
(en)
|
2017-12-15 |
2020-10-21 |
Juno Therapeutics, Inc. |
Anti-cct5 binding molecules and methods of use thereof
|
|
GB201721802D0
(en)
*
|
2017-12-22 |
2018-02-07 |
Almac Discovery Ltd |
Ror1-specific antigen binding molecules
|
|
BR112020011017A2
(pt)
|
2017-12-22 |
2020-11-17 |
Fate Therapeutics, Inc. |
células efetoras imunes intensificadas e uso das mesmas
|
|
MA51428A
(fr)
*
|
2017-12-22 |
2020-11-04 |
Bluebird Bio Inc |
Récepteur d'antigène chimérique multivalent
|
|
WO2019127215A1
(en)
*
|
2017-12-28 |
2019-07-04 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof
|
|
CA3087331A1
(en)
*
|
2017-12-29 |
2019-07-04 |
City Of Hope |
Meditope-enabled t cells
|
|
CN111867619A
(zh)
|
2018-01-03 |
2020-10-30 |
曲生物制品公司 |
过继性细胞治疗的先天寻靶
|
|
WO2019139972A1
(en)
|
2018-01-09 |
2019-07-18 |
Board Of Regents, The University Of Texas System |
T cell receptors for immunotherapy
|
|
CA3087476A1
(en)
*
|
2018-01-10 |
2019-07-18 |
The General Hospital Corporation |
Immune cells expressing a chimeric antigen receptor
|
|
US10561686B2
(en)
|
2018-01-12 |
2020-02-18 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expansion and uses thereof
|
|
CN108285486A
(zh)
*
|
2018-01-15 |
2018-07-17 |
浙江阿思科力生物科技有限公司 |
以cd20为靶点的特异性抗体、car-nk细胞及其制备和应用
|
|
WO2019144095A1
(en)
|
2018-01-22 |
2019-07-25 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Methods of use for car t cells
|
|
KR102115236B1
(ko)
*
|
2018-01-29 |
2020-05-27 |
(주)에스엠티바이오 |
췌장 또는 담관계암 치료를 위한 키메라 항원 수용체
|
|
CN111971059A
(zh)
|
2018-01-31 |
2020-11-20 |
细胞基因公司 |
使用过继细胞疗法和检查点抑制剂的组合疗法
|
|
CN111918972A
(zh)
|
2018-01-31 |
2020-11-10 |
朱诺治疗学股份有限公司 |
评估存在或不存在有复制能力的病毒的方法和试剂
|
|
AU2019218729B2
(en)
|
2018-02-06 |
2025-12-04 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors
|
|
CN108219004A
(zh)
*
|
2018-02-08 |
2018-06-29 |
吉林省拓华生物科技有限公司 |
双特异嵌合抗原受体修饰的t细胞、其制备方法及用途
|
|
US12344662B2
(en)
*
|
2018-02-09 |
2025-07-01 |
The Trustees Of Dartmouth College |
Chimeric antigen receptors for treatment of neurodegenerative diseases and disorders
|
|
WO2019165121A1
(en)
|
2018-02-21 |
2019-08-29 |
Board Of Regents, The University Of Texas System |
Methods for activation and expansion of natural killer cells and uses therof
|
|
JP7568224B2
(ja)
|
2018-02-23 |
2024-10-16 |
エンドサイト・インコーポレイテッド |
Ｃａｒ ｔ細胞療法のための配列決定法
|
|
WO2019170845A1
(en)
|
2018-03-09 |
2019-09-12 |
Ospedale San Raffaele S.R.L. |
Il-1 antagonist and toxicity induced by cell therapy
|
|
WO2019178085A1
(en)
|
2018-03-14 |
2019-09-19 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy
|
|
AU2019243315A1
(en)
|
2018-03-29 |
2020-09-24 |
Fate Therapeutics, Inc. |
Engineered immune effector cells and use thereof
|
|
CN108251392B
(zh)
*
|
2018-03-30 |
2021-04-20 |
广东溢多利生物科技股份有限公司 |
提高比活和热稳定性的葡萄糖氧化酶突变体及其编码基因和应用
|
|
CN112566698A
(zh)
|
2018-04-05 |
2021-03-26 |
朱诺治疗学股份有限公司 |
T细胞受体和表达该t细胞受体的工程化细胞
|
|
CN112585276A
(zh)
|
2018-04-05 |
2021-03-30 |
朱诺治疗学股份有限公司 |
产生表达重组受体的细胞的方法和相关组合物
|
|
EP3773633A4
(en)
|
2018-04-06 |
2022-01-26 |
The Regents of The University of California |
METHODS OF TREATMENT OF GLIOBLASTOMA
|
|
CA3096202A1
(en)
|
2018-04-06 |
2019-10-10 |
The Regents Of The University Of California |
Methods of treating egfrviii expressing glioblastomas
|
|
US10869888B2
(en)
*
|
2018-04-17 |
2020-12-22 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expansion and uses thereof
|
|
CN108715616A
(zh)
*
|
2018-04-27 |
2018-10-30 |
上海恒润达生生物科技有限公司 |
靶向人源化间皮素的嵌合抗原受体方法和用途
|
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
CA3091490A1
(en)
|
2018-04-27 |
2019-10-31 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Rapamycin resistant cells
|
|
US20210396739A1
(en)
|
2018-05-01 |
2021-12-23 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
BR112020022185A2
(pt)
|
2018-05-03 |
2021-02-02 |
Juno Therapeutics Inc |
terapia de combinação de uma terapia de células t do receptor de antígeno quimérico (car) e um inibidor de quinase
|
|
US20210213063A1
(en)
|
2018-05-25 |
2021-07-15 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
WO2019237035A1
(en)
|
2018-06-08 |
2019-12-12 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
|
CA3103610A1
(en)
|
2018-06-12 |
2019-12-19 |
The Regents Of The University Of California |
Single-chain bispecific chimeric antigen receptors for the treatment of cancer
|
|
IL279367B2
(en)
|
2018-06-13 |
2026-05-01 |
Novartis Ag |
BCMA chimeric antigen receptors and their uses
|
|
JP7097465B2
(ja)
|
2018-06-19 |
2022-07-07 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
キメラ抗原受容体細胞療法と併用するｉｌ－１０剤の組成およびその使用方法
|
|
CN110615842B
(zh)
*
|
2018-06-20 |
2023-05-09 |
上海隆耀生物科技有限公司 |
一种包含共刺激受体的嵌合抗原受体及应用
|
|
CA3099928A1
(en)
*
|
2018-06-22 |
2019-12-26 |
The General Hospital Corporation |
Chimeric antigen receptors targeting cd37 and cd19
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
KR20210031898A
(ko)
*
|
2018-07-13 |
2021-03-23 |
난징 레전드 바이오테크 씨오., 엘티디. |
전염병을 치료하기 위한 공동수용체 시스템
|
|
US10640562B2
(en)
|
2018-07-17 |
2020-05-05 |
Mcmaster University |
T cell-antigen coupler with various construct optimizations
|
|
US11110123B2
(en)
|
2018-07-17 |
2021-09-07 |
Triumvira Immunologics Usa, Inc. |
T cell-antigen coupler with various construct optimizations
|
|
CN112805378A
(zh)
|
2018-08-09 |
2021-05-14 |
朱诺治疗学股份有限公司 |
用于评估整合核酸的方法
|
|
BR112021002390A2
(pt)
|
2018-08-09 |
2021-05-11 |
Juno Therapeutics Inc |
processos para gerar células modificadas e suas composições
|
|
US12350316B2
(en)
|
2018-08-16 |
2025-07-08 |
Nantbio, Inc. |
IL7-IL 15 TxM compositions and methods
|
|
US12240915B2
(en)
|
2018-08-30 |
2025-03-04 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Chimeric antigen receptor cells for treating solid tumor
|
|
JP7504891B2
(ja)
|
2018-09-11 |
2024-06-24 |
ジュノー セラピューティクス インコーポレイテッド |
操作された細胞組成物のマススペクトロメトリー分析のための方法
|
|
CN109293781A
(zh)
*
|
2018-09-12 |
2019-02-01 |
中国人民解放军总医院 |
嵌合抗原受体及其基因和重组表达载体、cd19-cd20双靶向性的t细胞及其应用
|
|
WO2020061796A1
(en)
*
|
2018-09-26 |
2020-04-02 |
Hrain Biotechnology Co., Ltd. |
Bcma-and-cd19-targeting chimeric antigen receptor and uses thereof
|
|
KR20210072797A
(ko)
|
2018-10-05 |
2021-06-17 |
세인트 안나 킨더크렙스포르슝 |
키메라 항원 수용체(car) 그룹
|
|
EP3632460A1
(en)
|
2018-10-05 |
2020-04-08 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
EP3868783A4
(en)
*
|
2018-10-19 |
2022-01-19 |
Cartexell Inc. |
ANTI-L1CAM ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND CHIMERIC ANTIGEN RECEPTOR THEREOF
|
|
WO2020092057A1
(en)
|
2018-10-30 |
2020-05-07 |
Yale University |
Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
|
|
WO2020089343A1
(en)
|
2018-10-31 |
2020-05-07 |
Juno Therapeutics Gmbh |
Methods for selection and stimulation of cells and apparatus for same
|
|
US12473345B2
(en)
|
2018-11-01 |
2025-11-18 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
|
|
EP4578507A3
(en)
|
2018-11-01 |
2025-11-12 |
Gracell Biotechnologies (Shanghai) Co., Ltd. |
Compositions and methods for t cell engineering
|
|
US20210393691A1
(en)
|
2018-11-06 |
2021-12-23 |
Juno Therapeutics, Inc. |
Process for producing genetically engineered t cells
|
|
US12466892B2
(en)
|
2018-11-08 |
2025-11-11 |
The Regents Of The University Of California |
Systems and methods for targeting cancer cells
|
|
CN113573719A
(zh)
|
2018-11-08 |
2021-10-29 |
朱诺治疗学股份有限公司 |
治疗和t细胞调节的方法和组合
|
|
BR112021009420A2
(pt)
|
2018-11-16 |
2021-11-23 |
Juno Therapeutics Inc |
Métodos de dosagem de células t manipuladas para o tratamento de malignidades de células b
|
|
US20220033848A1
(en)
|
2018-11-19 |
2022-02-03 |
Board Of Regents, The University Of Texas System |
A modular, polycistronic vector for car and tcr transduction
|
|
US10918667B2
(en)
|
2018-11-20 |
2021-02-16 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expressing therapeutic agent and uses thereof
|
|
CN113226340A
(zh)
|
2018-11-26 |
2021-08-06 |
恩卡尔塔公司 |
同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
|
|
AU2019386140B2
(en)
|
2018-11-28 |
2026-05-28 |
Board Of Regents, The University Of Texas System |
Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
|
|
EP3886874B1
(en)
|
2018-11-29 |
2024-12-11 |
Board of Regents, The University of Texas System |
Methods for ex vivo expansion of natural killer cells and use thereof
|
|
KR20210110811A
(ko)
|
2018-11-30 |
2021-09-09 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 요법에서 ｂ 세포 악성 종양의 투약 및 치료 방법
|
|
EP4427810A3
(en)
|
2018-11-30 |
2024-12-04 |
Juno Therapeutics, Inc. |
Methods for treatment using adoptive cell therapy
|
|
JP7649239B2
(ja)
*
|
2018-11-30 |
2025-03-19 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
キメラ抗原受容体ファクトリおよびその使用方法
|
|
JP2022510207A
(ja)
|
2018-12-02 |
2022-01-26 |
フェイト セラピューティクス，インコーポレイテッド |
増強されたｉＰＳＣ派生エフェクター細胞を使用した免疫療法
|
|
KR20210099614A
(ko)
|
2018-12-04 |
2021-08-12 |
노파르티스 아게 |
Cd3에 대한 결합 분자 및 이의 용도
|
|
KR20250116790A
(ko)
*
|
2018-12-12 |
2025-08-01 |
카이트 파마 인코포레이티드 |
키메라 항원 수용체 및 car-t 세포 및 사용 방법
|
|
KR20210104836A
(ko)
*
|
2018-12-19 |
2021-08-25 |
리제너론 파아마슈티컬스, 인크. |
이중 특이적 항-cd28 x 항-cd22 항체 및 그의 용도
|
|
AU2019402189B2
(en)
|
2018-12-20 |
2023-04-13 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
EP3908613A4
(en)
*
|
2019-01-07 |
2022-10-19 |
Celluris Participações Ltda. |
BISPECIFIC IN-TANDEM RECEPTOR CAR AND METHODS FOR MODULATION OF THE TUMOR MICROAREA
|
|
WO2020150832A1
(en)
|
2019-01-24 |
2020-07-30 |
Valorisation-Hsj, Limited Partnership |
Cell-specific transcriptional regulatory sequences and uses thereof
|
|
EA202192103A1
(ru)
|
2019-01-29 |
2021-12-15 |
Джуно Терапьютикс, Инк. |
Антитела и химерные антигенные рецепторы, специфичные к орфанному рецептору типа рецеторной тирозинкиназы 1 (ror1)
|
|
JP2022519704A
(ja)
*
|
2019-02-08 |
2022-03-24 |
シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） |
キメラサイトカイン受容体
|
|
CN111544585B
(zh)
*
|
2019-02-11 |
2024-12-27 |
北京卡替医疗技术有限公司 |
一种可助推免疫细胞在体内扩增的佐剂
|
|
SG11202108655TA
(en)
|
2019-02-15 |
2021-09-29 |
Univ Southern California |
Lym-1 and lym-2 antibody compositions and improved car constructs
|
|
EP3924054B1
(en)
|
2019-02-15 |
2025-04-02 |
Novartis AG |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CA3123519A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
US20230348556A1
(en)
*
|
2019-02-21 |
2023-11-02 |
Arbele Limited |
Artificial immunosurveillance chimeric antigen receptor and cells expressing the same
|
|
SG11202109331QA
(en)
|
2019-03-01 |
2021-09-29 |
Iovance Biotherapeutics Inc |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
KR20210137085A
(ko)
|
2019-03-05 |
2021-11-17 |
엔카르타, 인크. |
Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
|
|
EP3934666A1
(en)
|
2019-03-08 |
2022-01-12 |
Autolus Limited |
Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
|
|
EP3712617B1
(en)
*
|
2019-03-19 |
2022-01-26 |
Miltenyi Biotec B.V. & Co. KG |
Method for providing personalized cells with chimeric antigen receptors (car)
|
|
KR102947433B1
(ko)
|
2019-04-12 |
2026-04-06 |
씨4 테라퓨틱스, 인코포레이티드 |
이카로스 및 아이올로스의 트리시클릭 분해제
|
|
WO2020219742A1
(en)
|
2019-04-24 |
2020-10-29 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
JP7711945B2
(ja)
|
2019-04-30 |
2025-07-23 |
センティ バイオサイエンシズ インコーポレイテッド |
キメラ受容体及びその使用方法
|
|
SG11202111372VA
(en)
|
2019-05-01 |
2021-11-29 |
Juno Therapeutics Inc |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
|
CA3136737A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
|
|
EP4778585A2
(en)
|
2019-05-07 |
2026-07-22 |
Gracell Bioscience (Shanghai) Co., Ltd. |
Engineered immune cell targeting bcma and use thereof
|
|
WO2020227446A1
(en)
*
|
2019-05-07 |
2020-11-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Enhancement of polypeptides and chimeric antigen receptors via hinge domains
|
|
CN113840912A
(zh)
*
|
2019-05-16 |
2021-12-24 |
南京传奇生物科技有限公司 |
包含识别分子的工程化免疫细胞
|
|
US20220228101A1
(en)
|
2019-06-07 |
2022-07-21 |
Juno Therapeutics, Inc. |
Automated t cell culture
|
|
SG11202113356XA
(en)
|
2019-06-12 |
2021-12-30 |
Juno Therapeutics Inc |
Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
|
|
AU2020295715A1
(en)
*
|
2019-06-19 |
2022-02-17 |
Julius-Maximilians-Universität Würzburg |
Ultramodular IgG3-based spacer domain and multi-function site for implementation in chimeric antigen receptor design
|
|
KR20220035190A
(ko)
|
2019-07-17 |
2022-03-21 |
페이트 세러퓨틱스, 인코포레이티드 |
면역 효과기 세포 조작 및 이의 용도
|
|
EP4003407A1
(en)
|
2019-07-23 |
2022-06-01 |
Mnemo Therapeutics |
Immune cells defective for suv39h1
|
|
CN112390891B
(zh)
*
|
2019-08-14 |
2022-06-03 |
苏州方德门达新药开发有限公司 |
嵌合抗原受体及其构建方法和应用
|
|
US12702708B2
(en)
|
2019-08-21 |
2026-08-11 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Presenting cell and use thereof in cell therapy
|
|
KR20220066892A
(ko)
|
2019-08-22 |
2022-05-24 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ｔ 세포 요법 및 제스트 동족체 2의 인핸서 (ｅｚｈ2) 억제제의 병용 요법 및 관련 방법
|
|
CN114600172A
(zh)
|
2019-08-30 |
2022-06-07 |
朱诺治疗学股份有限公司 |
用于将细胞分类的机器学习方法
|
|
JP7711045B2
(ja)
|
2019-09-02 |
2025-07-22 |
アンスティテュ・クリー |
腫瘍ネオアンチゲンペプチドを標的とする免疫療法
|
|
WO2021046243A2
(en)
|
2019-09-03 |
2021-03-11 |
Myeloid Therapeutics, Inc. |
Methods and compositions for genomic integration
|
|
US12551560B2
(en)
|
2019-09-09 |
2026-02-17 |
Scribe Therapeutics Inc. |
Compositions and methods for use in immunotherapy
|
|
WO2021072353A1
(en)
*
|
2019-10-11 |
2021-04-15 |
The Regents Of The University Of California |
Chimeric antigen receptors against human cytomegalovirus
|
|
US20220401539A1
(en)
|
2019-10-22 |
2022-12-22 |
Institut Curie |
Immunotherapy Targeting Tumor Neoantigenic Peptides
|
|
MX2022005145A
(es)
|
2019-10-30 |
2022-06-29 |
Juno Therapeutics Gmbh |
Dispositivos de estimulación y/o selección celular y método de uso.
|
|
EP4054623A1
(en)
|
2019-11-07 |
2022-09-14 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and (s)-3-[4-(4-morpholin-4 ylmethyl-benzyloxy)-l-oxo-l,3-dihydro-isoindol-2-yl]- piperidine-2,6-dione
|
|
JP7805928B2
(ja)
|
2019-11-26 |
2026-01-26 |
ノバルティス アーゲー |
Ｃｄ１９及びｃｄ２２キメラ抗原受容体及びその使用
|
|
EP4070097A1
(en)
|
2019-12-06 |
2022-10-12 |
Juno Therapeutics, Inc. |
Methods related to toxicity and response associated with cell therapy for treating b cell malignancies
|
|
WO2021113776A1
(en)
|
2019-12-06 |
2021-06-10 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
|
|
WO2021113780A1
(en)
|
2019-12-06 |
2021-06-10 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
|
|
US20230057071A1
(en)
|
2019-12-20 |
2023-02-23 |
Novartis Ag |
Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
|
|
JP7088902B2
(ja)
*
|
2019-12-27 |
2022-06-21 |
クレージュ メディカル カンパニー，リミテッド |
キメラ抗原受容体タンパク質をコードする核酸およびキメラ抗原受容体タンパク質を発現するｔリンパ球
|
|
CN115315273A
(zh)
|
2020-01-14 |
2022-11-08 |
辛德凯因股份有限公司 |
Il-2直向同源物及其使用方法
|
|
KR20220130158A
(ko)
|
2020-01-23 |
2022-09-26 |
더 칠드런스 메디칼 센터 코포레이션 |
인간 만능 줄기 세포로부터의 무-간질 t 세포 분화
|
|
US20230071910A1
(en)
|
2020-01-24 |
2023-03-09 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy
|
|
US20230090117A1
(en)
|
2020-01-28 |
2023-03-23 |
Juno Therapeutics, Inc. |
Methods for t cell transduction
|
|
IL295063A
(en)
|
2020-02-04 |
2022-09-01 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Chimeric antigen receptors (car) against dinitrophenol
|
|
CA3169672A1
(en)
|
2020-02-12 |
2021-08-19 |
Juno Therapeutics, Inc. |
Cd19-directed chimeric antigen receptor t cell compositions and methods and uses thereof
|
|
JP2023519099A
(ja)
|
2020-02-12 |
2023-05-10 |
ジュノー セラピューティクス インコーポレイテッド |
Ｂｃｍａ指向性キメラ抗原受容体ｔ細胞組成物ならびにその方法および使用
|
|
WO2021167908A1
(en)
|
2020-02-17 |
2021-08-26 |
Board Of Regents, The University Of Texas System |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
|
WO2021168000A1
(en)
*
|
2020-02-17 |
2021-08-26 |
University Of Virginia Patent Foundation |
CAR T CELLS TARGETING THE INTEGRIN ALPHAv BETA3 EXHIBIT ROBUST ANTI-TUMOR RESPONSES AGAINST GLIOMAS AND OTHER SOLID TUMOR MALIGNANCIES
|
|
US12076343B2
(en)
|
2020-02-19 |
2024-09-03 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Engineered safety in cell therapy
|
|
IL295878A
(en)
|
2020-02-27 |
2022-10-01 |
Novartis Ag |
Methods for producing cells expressing a chimeric antigen receptor
|
|
US20230374085A1
(en)
*
|
2020-03-11 |
2023-11-23 |
City Of Hope |
Dual-targeting chimeric antigen receptor modified t cells comprising il-13 and chlorotoxin for cancer treatment
|
|
CN113402612A
(zh)
|
2020-03-17 |
2021-09-17 |
西比曼生物科技（香港）有限公司 |
靶向cd19和cd20的联合嵌合抗原受体及其应用
|
|
EP4121447A1
(en)
*
|
2020-03-20 |
2023-01-25 |
Lyell Immunopharma, Inc. |
Novel recombinant cell surface markers
|
|
JP7840865B2
(ja)
|
2020-03-31 |
2026-04-06 |
フレッド ハッチンソン キャンサー センター |
キメラ抗原受容体ターゲティングｃｄ３３
|
|
IL297147B1
(en)
|
2020-04-10 |
2026-05-01 |
Juno Therapeutics Inc |
Methods and uses related to engineered cell therapy with a chimeric antigen receptor directed against a B-cell maturation antigen
|
|
US12703750B2
(en)
|
2020-04-11 |
2026-08-11 |
Northwestern University |
Humanized antibody targeting the tumor associated antigen IL13Ra2
|
|
WO2021216739A1
(en)
*
|
2020-04-23 |
2021-10-28 |
Baylor College Of Medicine |
Overcoming the tumor microenvironment for cell therapy by targeting myeloid derived suppressor cells through a trail-r2 specific receptor
|
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
JP2023525049A
(ja)
*
|
2020-05-08 |
2023-06-14 |
シアトル・チルドレンズ・ホスピタル・ドゥーイング／ビジネス／アズ・シアトル・チルドレンズ・リサーチ・インスティテュート |
ナチュラルキラー細胞を標的とするキメラ抗原受容体（ｃａｒ）
|
|
EP4149952A1
(en)
|
2020-05-12 |
2023-03-22 |
Institut Curie |
Neoantigenic epitopes associated with sf3b1 mutations
|
|
KR20230022868A
(ko)
|
2020-05-13 |
2023-02-16 |
주노 쎄러퓨티크스 인코퍼레이티드 |
재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
|
|
KR20230024283A
(ko)
|
2020-05-13 |
2023-02-20 |
주노 쎄러퓨티크스 인코퍼레이티드 |
임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도
|
|
CN115803084A
(zh)
|
2020-05-21 |
2023-03-14 |
得克萨斯大学体系董事会 |
具有vgll1特异性的t细胞受体和其用途
|
|
WO2021247525A1
(en)
*
|
2020-06-02 |
2021-12-09 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
Dual egfr-muc1 chimeric antigen receptor t cells
|
|
US12043654B2
(en)
|
2020-06-02 |
2024-07-23 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Anti-GCC antibody and CAR thereof for treating digestive system cancer
|
|
US20230332104A1
(en)
|
2020-06-11 |
2023-10-19 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
|
KR20230040337A
(ko)
|
2020-06-19 |
2023-03-22 |
페이트 세러퓨틱스, 인코포레이티드 |
면역요법 사용을 위한 iPSC-유래 이펙터 세포 유형들의 조합
|
|
EP4168007A1
(en)
|
2020-06-23 |
2023-04-26 |
Novartis AG |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
EP4171616A1
(en)
|
2020-06-26 |
2023-05-03 |
Juno Therapeutics GmbH |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
|
JP7886313B2
(ja)
|
2020-07-30 |
2026-07-07 |
アンスティテュ・クリー |
Ｓｏｃｓ１に欠陥のある免疫細胞
|
|
EP4188549A1
(en)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
KR20230095918A
(ko)
|
2020-08-05 |
2023-06-29 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ror1-표적 결합 도메인에 대한 항이디오타입 항체 및 관련 조성물 및 방법
|
|
CA3188988A1
(en)
|
2020-08-13 |
2022-02-17 |
Sidi CHEN |
Compositions and methods for engineering and selection of car t cells with desired phenotypes
|
|
WO2022036495A1
(en)
|
2020-08-17 |
2022-02-24 |
Utc Therapeutics Inc. |
Lymphocytes-antigen presenting cells co-stimulators and uses thereof
|
|
WO2022036458A1
(en)
|
2020-08-21 |
2022-02-24 |
12343096 Canada Inc. |
Modular assembly receptors and uses thereof
|
|
WO2022046935A2
(en)
*
|
2020-08-26 |
2022-03-03 |
The Regents Of The University Of California |
Methods and compositions for treating glioblastoma
|
|
CN116568812A
(zh)
*
|
2020-09-08 |
2023-08-08 |
亘喜生物科技（上海）有限公司 |
用于t细胞工程化的组合物和方法
|
|
WO2022082030A2
(en)
|
2020-10-15 |
2022-04-21 |
Gritstone Bio, Inc. |
Antigen-binding proteins and related methods of use
|
|
KR20230112632A
(ko)
|
2020-10-23 |
2023-07-27 |
애셔 바이오테라퓨틱스, 인크. |
면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
|
|
US20260008864A1
(en)
*
|
2020-10-28 |
2026-01-08 |
City Of Hope |
Bispecific anti-cd38-cd3 binders
|
|
WO2022098914A1
(en)
*
|
2020-11-04 |
2022-05-12 |
Fate Therapeutics, Inc. |
Engineered ipsc and persistent immune effector cells
|
|
CA3201499A1
(en)
|
2020-11-13 |
2022-05-19 |
Catamaran Bio, Inc. |
Genetically modified natural killer cells and methods of use thereof
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
IL303269A
(en)
|
2020-12-03 |
2023-07-01 |
Century Therapeutics Inc |
Genetically engineered cells and uses thereof
|
|
WO2022133030A1
(en)
|
2020-12-16 |
2022-06-23 |
Juno Therapeutics, Inc. |
Combination therapy of a cell therapy and a bcl2 inhibitor
|
|
TW202241935A
(zh)
|
2020-12-18 |
2022-11-01 |
美商世紀治療股份有限公司 |
具有可調適受體專一性之嵌合抗原受體系統
|
|
KR20230151513A
(ko)
|
2021-01-11 |
2023-11-01 |
사나 바이오테크놀로지, 인크. |
Cd8 표적 바이러스 벡터의 용도
|
|
WO2022155503A1
(en)
|
2021-01-14 |
2022-07-21 |
Gritstone Bio, Inc. |
Multi-specific antibodies and methods of use
|
|
CN114807042B
(zh)
*
|
2021-01-22 |
2024-09-03 |
南京助天中科科技发展有限公司 |
一种嵌合抗原受体改造的nk细胞及其制备方法与应用
|
|
CN114907485B
(zh)
*
|
2021-02-08 |
2024-04-26 |
浙江大学 |
一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体
|
|
WO2022173950A1
(en)
*
|
2021-02-11 |
2022-08-18 |
The Trustees Of The University Of Pennsylvania |
Ccr4-targeting chimeric antigen receptor cell therapy
|
|
AU2022227686A1
(en)
|
2021-02-25 |
2023-07-27 |
Lyell Immunopharma, Inc. |
Ror1 targeting chimeric antigen receptor
|
|
KR20230165771A
(ko)
|
2021-03-03 |
2023-12-05 |
주노 쎄러퓨티크스 인코퍼레이티드 |
T 세포 요법 및 dgk 억제제의 조합
|
|
IL305804A
(en)
|
2021-03-11 |
2023-11-01 |
Inst Curie |
Transmembrane neoantigenic peptides
|
|
US20250352577A1
(en)
|
2021-03-11 |
2025-11-20 |
Mnemo Therapeutics |
Tumor neoantigenic peptides and uses thereof
|
|
CA3212964A1
(en)
|
2021-03-11 |
2022-09-15 |
Mnemo Therapeutics |
Tumor neoantigenic peptides
|
|
US20240168012A1
(en)
|
2021-03-22 |
2024-05-23 |
Juno Therapeutics, Inc. |
Methods of determining potency of a therapeutic cell composition
|
|
WO2022204071A1
(en)
|
2021-03-22 |
2022-09-29 |
Juno Therapeutics, Inc. |
Method to assess potency of viral vector particles
|
|
CN115109754B
(zh)
*
|
2021-03-23 |
2025-04-01 |
复星凯瑞(上海)生物科技有限公司 |
抗EGFR和cMet双特异性嵌合抗原受体及其应用
|
|
CN117858719A
(zh)
|
2021-03-29 |
2024-04-09 |
朱诺治疗学股份有限公司 |
使用检查点抑制剂疗法和car t细胞疗法的组合进行给药和治疗的方法
|
|
IL307257A
(en)
|
2021-03-29 |
2023-11-01 |
Juno Therapeutics Inc |
A combination of car cell therapy and an immunomodulatory compound for the treatment of lymphoma
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
CN113735978B
(zh)
*
|
2021-04-22 |
2023-06-30 |
河北森朗生物科技有限公司 |
靶向cd19的嵌合抗原受体、制备方法及其应用
|
|
CA3217028A1
(en)
|
2021-04-22 |
2022-10-27 |
Baylor College Of Medicine |
Methods of engineering immune cells having reduced fratricidal activity
|
|
AR125468A1
(es)
|
2021-04-27 |
2023-07-19 |
Novartis Ag |
Sistema de producción de vectores virales
|
|
CN117916256A
(zh)
|
2021-05-06 |
2024-04-19 |
朱诺治疗学有限公司 |
用于刺激和转导t细胞的方法
|
|
WO2022241029A1
(en)
|
2021-05-11 |
2022-11-17 |
Myeloid Therapeutics, Inc. |
Methods and compositions for genomic integration
|
|
AU2022283819A1
(en)
|
2021-06-01 |
2024-01-04 |
Triumvira Immunologics Usa, Inc. |
Claudin 18.2 t cell-antigen couplers and uses thereof
|
|
US11453723B1
(en)
|
2021-06-25 |
2022-09-27 |
Mcmaster University |
BCMA T cell-antigen couplers and uses thereof
|
|
JP2024531910A
(ja)
|
2021-08-04 |
2024-09-03 |
ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト |
Ｌａｔ活性化キメラ抗原受容体ｔ細胞及びその使用方法
|
|
EP4381081A1
(en)
|
2021-08-04 |
2024-06-12 |
Sana Biotechnology, Inc. |
Use of cd4-targeted viral vectors
|
|
CA3228773A1
(en)
*
|
2021-08-12 |
2023-02-16 |
Gaurav KHARYA |
Chimeric antigen receptors (car) for b cell malignancies
|
|
EP4394043A4
(en)
*
|
2021-08-24 |
2025-09-03 |
Cells & Genes Biotech Shanghai Co Ltd |
CELL MODIFICATION METHOD
|
|
GB202112923D0
(en)
|
2021-09-10 |
2021-10-27 |
Ucl Business Ltd |
Binding domain
|
|
US20250009879A1
(en)
*
|
2021-11-22 |
2025-01-09 |
The Asan Foundation |
Natural killer cell-specific chimeric antigen receptor and use thereof
|
|
WO2023105000A1
(en)
|
2021-12-09 |
2023-06-15 |
Zygosity Limited |
Vector
|
|
EP4448775A1
(en)
|
2021-12-17 |
2024-10-23 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae attachment glycoproteins
|
|
US20250059239A1
(en)
|
2021-12-17 |
2025-02-20 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae fusion glycoproteins
|
|
JP2025501272A
(ja)
|
2021-12-28 |
2025-01-17 |
ムネモ・セラピューティクス |
不活性化されたｓｕｖ３９ｈ１及び改変ｔｃｒを有する免疫細胞
|
|
AU2023209589A1
(en)
|
2022-01-21 |
2024-08-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Modulation of suv39h1 expression by rnas
|
|
KR20240137075A
(ko)
|
2022-01-28 |
2024-09-19 |
주노 쎄러퓨티크스 인코퍼레이티드 |
세포 조성물의 제조 방법
|
|
WO2023150518A1
(en)
|
2022-02-01 |
2023-08-10 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
|
US20250135002A1
(en)
*
|
2022-02-04 |
2025-05-01 |
Duke University |
Compositions for and method of effecting tumor cell death
|
|
WO2023173137A1
(en)
|
2022-03-11 |
2023-09-14 |
Yale University |
Compositions and methods for efficient and stable genetic modification of eukaryotic cells
|
|
CA3245554A1
(en)
|
2022-03-18 |
2023-09-21 |
The Regents Of The University Of Colorado, A Body Corporate |
Genetically modified T lymphocyte co-receptors and their methods of use
|
|
CN119816320A
(zh)
|
2022-03-24 |
2025-04-11 |
居里研究所 |
靶向胶质母细胞瘤中肿瘤转座元件衍生的新抗原肽的免疫疗法
|
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
US20250304913A1
(en)
|
2022-04-06 |
2025-10-02 |
The Regents Of The University Of Colorado, A Body Corporate |
Chimeric antigen receptor t cells and methods of use thereof
|
|
WO2023196921A1
(en)
|
2022-04-06 |
2023-10-12 |
The Regents Of The University Of Colorado, A Body Corporate |
Granzyme expressing t cells and methods of use
|
|
KR20250004622A
(ko)
|
2022-04-08 |
2025-01-08 |
페이트 세러퓨틱스, 인코포레이티드 |
종양 표적화를 위한 키메라 항원 수용체
|
|
KR20250005097A
(ko)
|
2022-04-08 |
2025-01-09 |
페이트 세러퓨틱스, 인코포레이티드 |
고형 종양 표적화 골격을 갖는 세포 및 이의 용도
|
|
WO2023211972A1
(en)
|
2022-04-28 |
2023-11-02 |
Medical University Of South Carolina |
Chimeric antigen receptor modified regulatory t cells for treating cancer
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
US20250297282A1
(en)
|
2022-05-05 |
2025-09-25 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
|
US20250302954A1
(en)
|
2022-05-11 |
2025-10-02 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
EP4279085A1
(en)
|
2022-05-20 |
2023-11-22 |
Mnemo Therapeutics |
Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
|
|
WO2023230581A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
|
JP2025521543A
(ja)
|
2022-06-22 |
2025-07-10 |
ジュノー セラピューティクス インコーポレイテッド |
Ｃｄ１９標的ｃａｒ ｔ細胞のセカンドライン治療のための処置方法
|
|
WO2024006960A1
(en)
|
2022-06-29 |
2024-01-04 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids
|
|
US20260061051A1
(en)
|
2022-08-26 |
2026-03-05 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
|
|
KR20250061756A
(ko)
|
2022-09-08 |
2025-05-08 |
주노 쎄러퓨티크스 인코퍼레이티드 |
T 세포 요법과 연속적 또는 간헐적 dgk 억제제 투여의 조합
|
|
CN117305248A
(zh)
*
|
2022-09-09 |
2023-12-29 |
复星凯特生物科技有限公司 |
抗EGFR和cMet双特异性嵌合抗原受体及其应用
|
|
WO2024062138A1
(en)
|
2022-09-23 |
2024-03-28 |
Mnemo Therapeutics |
Immune cells comprising a modified suv39h1 gene
|
|
EP4602174A1
(en)
|
2022-10-13 |
2025-08-20 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
|
JP2026519263A
(ja)
|
2022-10-26 |
2026-06-15 |
ノバルティス アーゲー |
レンチウイルス製剤
|
|
US20260124242A1
(en)
|
2022-11-04 |
2026-05-07 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
|
CN121100267A
(zh)
|
2022-12-09 |
2025-12-09 |
朱诺治疗学股份有限公司 |
使用全息成像预测细胞表型的机器学习方法
|
|
US20260232729A1
(en)
|
2023-02-03 |
2026-08-13 |
C3S2 Gmbh |
Methods for non-viral manufacturing of engineered immune cells
|
|
WO2024182516A1
(en)
|
2023-02-28 |
2024-09-06 |
Juno Therapeutics, Inc. |
Cell therapy for treating systemic autoimmune diseases
|
|
WO2024191898A2
(en)
*
|
2023-03-10 |
2024-09-19 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Methods and compositions for cellular immunotherapy - fib2
|
|
WO2024191900A2
(en)
*
|
2023-03-10 |
2024-09-19 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Methods and compositions for cellular immunotherapy – fib4
|
|
WO2024192134A1
(en)
*
|
2023-03-13 |
2024-09-19 |
Immpact Bio Usa, Inc. |
Bispecific cars for the treatment of lupus and autoimmune diseases
|
|
PE20260290A1
(es)
|
2023-03-31 |
2026-02-10 |
Abelzeta Inc |
Receptores de antigeno quimericos biespecificos dirigidos a cd20 y bcma
|
|
WO2024220560A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Engineered protein g fusogens and related lipid particles and methods thereof
|
|
KR20250169631A
(ko)
|
2023-04-18 |
2025-12-03 |
주노 쎄러퓨티크스 인코퍼레이티드 |
치료 세포 조성물의 효력을 평가하기 위한 세포독성 검정
|
|
WO2024220598A2
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Lentiviral vectors with two or more genomes
|
|
EP4698666A1
(en)
|
2023-04-18 |
2026-02-25 |
Sana Biotechnology, Inc. |
Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
|
|
WO2024226829A2
(en)
|
2023-04-26 |
2024-10-31 |
Yale University |
Enpp3-binding molecules, compositions formed therefrom, and methods of use thereof for the treatment of cancer
|
|
WO2024226858A1
(en)
|
2023-04-26 |
2024-10-31 |
Juno Therapeutics, Inc. |
Methods for viral vector manufacturing
|
|
EP4716851A2
(en)
|
2023-05-23 |
2026-04-01 |
Juno Therapeutics, Inc. |
Activation markers of t cells and method for assessing t cell activation
|
|
WO2024243441A1
(en)
|
2023-05-24 |
2024-11-28 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2025054202A1
(en)
|
2023-09-05 |
2025-03-13 |
Sana Biotechnology, Inc. |
Method of screening a sample comprising a transgene with a unique barcode
|
|
WO2025052001A1
(en)
|
2023-09-07 |
2025-03-13 |
Mnemo Therapeutics |
Methods and compositions for improving immune response
|
|
EP4520334A1
(en)
|
2023-09-07 |
2025-03-12 |
Mnemo Therapeutics |
Methods and compositions for improving immune response
|
|
CN121969385A
(zh)
|
2023-09-11 |
2026-05-01 |
丹娜-法伯癌症研究院 |
含有il-2变体以增强car t细胞的功能性的car-衔接子
|
|
WO2025082603A1
(en)
|
2023-10-18 |
2025-04-24 |
Institut Curie |
Engineered immune cells overexpressing cd74 molecule
|
|
WO2025096975A1
(en)
|
2023-11-02 |
2025-05-08 |
The Regents Of The University Of Colorado, A Body Corporate |
Compositions and methods of enhancing immune cell therapies by runx2 modulation
|
|
WO2025147545A1
(en)
|
2024-01-03 |
2025-07-10 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids and related methods and uses
|
|
AU2025208175A1
(en)
|
2024-01-12 |
2026-06-25 |
Sana Biotechnology, Inc. |
Safety switches to control in vitro and in vivo proliferation of cell therapy products
|
|
WO2025163107A1
(en)
|
2024-02-01 |
2025-08-07 |
Institut Gustave Roussy |
Immune cells defective for znf217 and uses thereof
|
|
WO2025176853A1
(en)
|
2024-02-22 |
2025-08-28 |
Miltenyi Biotec B.V. & Co. KG |
Cd4- or cd8-targeted retroviral vector particles for generation of cells expressing a bispecific chimeric antigen receptor
|
|
WO2025184421A1
(en)
|
2024-02-28 |
2025-09-04 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods
|
|
WO2025231185A1
(en)
|
2024-05-01 |
2025-11-06 |
Legend Biotech Ireland Limited |
Viral glycoprotein variants and uses thereof
|
|
US20250345431A1
(en)
|
2024-05-10 |
2025-11-13 |
Juno Therapeutics, Inc. |
Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
|
|
NL2037811B1
(en)
|
2024-05-29 |
2025-12-12 |
Univ Oslo |
Treatment for Cancer
|
|
NL2037929B1
(en)
|
2024-06-11 |
2026-01-12 |
Prinses Maxima Centrum Voor Kinderoncologie B V |
Brain Organoid
|
|
WO2026020055A2
(en)
|
2024-07-18 |
2026-01-22 |
Juno Therapeutics, Inc. |
Methods for assessing exosomes in a cell composition and related uses
|
|
WO2026025092A1
(en)
|
2024-07-26 |
2026-01-29 |
Juno Therapeutics, Inc. |
Synthetic promoters for t cell expression
|
|
WO2026062222A1
(en)
|
2024-09-20 |
2026-03-26 |
Institut Curie |
Novel protein isoforms and uses
|
|
WO2026096515A1
(en)
|
2024-10-28 |
2026-05-07 |
Legend Biotech Ireland Limited |
Viral glycoprotein variants and uses thereof
|
|
GB202417285D0
(en)
|
2024-11-25 |
2025-01-08 |
Univ Oxford Innovation Ltd |
Expanded t cell population
|
|
GB202418460D0
(en)
|
2024-12-16 |
2025-01-29 |
Univ Oxford Innovation Ltd |
Multivalent binding proteins
|
|
WO2026136848A2
(en)
|
2024-12-20 |
2026-06-25 |
Juno Therapeutics, Inc. |
Cd70-targeted cars and engineered cells comprising same and related methods
|